PT94064A - Processo para a preparacao de novos conjugados de antraciclina que comportam um novo ligante e de composicoes farmaceuticas que os contem - Google Patents

Processo para a preparacao de novos conjugados de antraciclina que comportam um novo ligante e de composicoes farmaceuticas que os contem

Info

Publication number
PT94064A
PT94064A PT94064A PT9406490A PT94064A PT 94064 A PT94064 A PT 94064A PT 94064 A PT94064 A PT 94064A PT 9406490 A PT9406490 A PT 9406490A PT 94064 A PT94064 A PT 94064A
Authority
PT
Portugal
Prior art keywords
anthracycline
conjugates
ligand
pharmaceutical compositions
preparation
Prior art date
Application number
PT94064A
Other languages
English (en)
Other versions
PT94064B (pt
Inventor
Takushi Kaneko
Robert S Greenfield
Gary R Braslawsky
Lee J Olech
Peter A Kiener
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/353,729 external-priority patent/US5122368A/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PT94064A publication Critical patent/PT94064A/pt
Publication of PT94064B publication Critical patent/PT94064B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
PT94064A 1989-05-17 1990-05-16 Processo para a preparacao de novos conjugados de antraciclina que comportam um novo ligante e de composicoes farmaceuticas que os contem PT94064B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/353,729 US5122368A (en) 1988-02-11 1989-05-17 Anthracycline conjugates having a novel linker and methods for their production

Publications (2)

Publication Number Publication Date
PT94064A true PT94064A (pt) 1991-01-08
PT94064B PT94064B (pt) 1997-07-31

Family

ID=23390328

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94064A PT94064B (pt) 1989-05-17 1990-05-16 Processo para a preparacao de novos conjugados de antraciclina que comportam um novo ligante e de composicoes farmaceuticas que os contem

Country Status (19)

Country Link
EP (1) EP0398305B1 (pt)
JP (1) JP3062696B2 (pt)
KR (1) KR0136899B1 (pt)
AT (1) ATE150321T1 (pt)
AU (1) AU631638B2 (pt)
CA (1) CA2016584C (pt)
DE (1) DE69030213T2 (pt)
DK (1) DK0398305T3 (pt)
ES (1) ES2099075T3 (pt)
FI (1) FI102356B (pt)
GR (1) GR3023784T3 (pt)
HK (1) HK1005018A1 (pt)
IE (1) IE81109B1 (pt)
IL (1) IL94379A (pt)
MY (1) MY131039A (pt)
NO (1) NO300691B1 (pt)
NZ (1) NZ233696A (pt)
PT (1) PT94064B (pt)
ZA (1) ZA903757B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU638971B2 (en) * 1990-02-14 1993-07-15 Bristol-Myers Squibb Company Anthracycline immunoconjugates having a novel linker and methods for their production
CA2048089A1 (en) * 1990-09-17 1992-03-18 Wolfgang A. Wrasidlo Chemical conjugation of morpholino anthracyclines to antibodies
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US7033765B1 (en) 1997-02-20 2006-04-25 Toronto Research Chemicals, Inc. Site-specific drug delivery
IL131445A0 (en) * 1997-02-20 2001-01-28 David S Dime Site-specific drug delivery
GB9724838D0 (en) * 1997-11-26 1998-01-21 Franks Christopher R Compositions
EP1305051A4 (en) * 2000-06-28 2007-01-10 Ward Page Faulk TARGETED ADMINISTRATION OF CYTOTOXIC ACTIVITIES A) TO ACTIVATED LYMPHOCYTES IN PATIENTS WITH TRANSPLANTED ORGANS, B) AS RADIATION SENSITIATORS TO CANCER CELLS IN RADIATION-TREATED PATIENTS, AND C) IN VITAMIN-BINDING PROTEINS AS ACTIVE INGREDIENTS IN DIAGNOSIS AND TREATMENT OF CANCER
AU2002216864A1 (en) * 2000-12-21 2002-07-01 Mcgill University Conjugates of antibodies and anticancer drugs
NZ511705A (en) * 2001-05-14 2004-03-26 Horticulture & Food Res Inst Methods and rapid immunoassay device for detecting progesterone and other steroids
KR100507968B1 (ko) * 2001-08-18 2005-08-17 한국과학기술연구원 자기집합체를 형성하는 항암제-키토산 복합체 및 그의제조방법
KR20070108953A (ko) 2003-04-22 2007-11-13 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. 펩타이드 벡터
US9011880B2 (en) 2003-10-21 2015-04-21 Igf Oncology, Llc Compounds and methods for treating cancer
CA2542834C (en) * 2003-10-21 2012-04-24 Igf Oncology, Llc Conjugates or co-administration of igf-1 receptor ligands with anti-cancer chemotherapeutic agents
WO2005084390A2 (en) * 2004-03-02 2005-09-15 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
EP1695717A1 (en) * 2005-02-23 2006-08-30 Ludwig-Maximilians-Universität Transport of nano-and macromolecular structures into cytoplasm and nucleus of cells
EP2303332B1 (en) * 2008-07-15 2014-12-31 Genentech, Inc. Anthracycline conjugates, process for their preparation and their use as antitumor compounds
AU2015204540B2 (en) 2014-01-12 2020-03-19 Igf Oncology, Llc Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
EP3191134B1 (en) * 2014-09-12 2019-11-20 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
CA3059593A1 (en) 2017-05-21 2018-11-29 Igf Oncology, Llc An insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957755A (en) * 1967-10-18 1976-05-18 Rhone-Poulenc S.A. Naphthacene derivatives
US4112217A (en) * 1977-09-02 1978-09-05 Sri International Bis-hydrazones of daunomycin and adriamycin
US4263428A (en) * 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US5162512A (en) * 1982-03-09 1992-11-10 Cytogen Corporation Amine derivatives of anthracycline antibodies
US4950738A (en) * 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics
GB8610551D0 (en) * 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
AU638971B2 (en) * 1990-02-14 1993-07-15 Bristol-Myers Squibb Company Anthracycline immunoconjugates having a novel linker and methods for their production

Also Published As

Publication number Publication date
IL94379A0 (en) 1991-03-10
IE81109B1 (en) 2000-03-08
CA2016584C (en) 1999-06-29
FI902387A0 (fi) 1990-05-14
NO902197L (no) 1990-11-19
IE901764L (en) 1990-11-17
DE69030213D1 (de) 1997-04-24
CA2016584A1 (en) 1990-11-17
KR0136899B1 (ko) 1998-04-25
ZA903757B (en) 1992-01-29
NO902197D0 (no) 1990-05-16
PT94064B (pt) 1997-07-31
FI102356B1 (fi) 1998-11-30
DE69030213T2 (de) 1997-10-16
JP3062696B2 (ja) 2000-07-12
FI102356B (fi) 1998-11-30
IL94379A (en) 1997-02-18
HK1005018A1 (en) 1998-12-18
EP0398305A3 (en) 1991-03-20
ES2099075T3 (es) 1997-05-16
EP0398305B1 (en) 1997-03-19
JPH0327321A (ja) 1991-02-05
MY131039A (en) 2007-07-31
DK0398305T3 (da) 1997-06-23
KR900017597A (ko) 1990-12-19
NO300691B1 (no) 1997-07-07
NZ233696A (en) 1992-04-28
AU5511790A (en) 1990-11-22
AU631638B2 (en) 1992-12-03
GR3023784T3 (en) 1997-09-30
ATE150321T1 (de) 1997-04-15
EP0398305A2 (en) 1990-11-22

Similar Documents

Publication Publication Date Title
PT89683A (pt) Processo para a preparacao de imunoconjugados de antraciclina comportando novos ligandos
PT94064A (pt) Processo para a preparacao de novos conjugados de antraciclina que comportam um novo ligante e de composicoes farmaceuticas que os contem
PT97639A (pt) Processo para a preparacao de hidrazinas n-substituidas bifuncionais e de composicoes farmaceuticas que as contem
Beitz et al. Antitumor activity of basic fibroblast growth factor-saporin mitotoxin in vitro and in vivo
PT730608E (pt) Composicoes compreendendo hidratos de carbono e proeinas relacionadas pelo complemento e metodos para produzir e utilizar as referidas composicoes
HUP0100507A2 (hu) Polietilén-glikol-GRF konjugátumok, eljárás azok helyspecifikus előállítására, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
HUT74578A (en) Pharmaceutical compositions containing antracyclin glycosides bound with polymers and process for producing them
CA2010164A1 (en) Anthracycline immunoconjugates having a novel linker and methods for their production

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19970430

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20111031

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20120430